Preclinical evaluation of a third-generation absorbable antibacterial envelope

Area of Science:

• Biomedical Engineering
• Infectious Diseases
• Materials Science

Background:

• The TYRX (Medtronic) absorbable antibacterial envelope stabilizes implantable cardiac devices and reduces infection.
• A third-generation envelope was developed with a redesigned mesh and enhanced form factor to reduce surface roughness, while maintaining identical polymer coating and antibiotic concentrations as the second-generation envelope.

Purpose of the Study:

• To compare the drug elution, bacterial challenge efficacy, stabilization, and absorption of second-generation versus third-generation TYRX envelopes.

Main Methods:

• Antibiotic elution assessed in vitro and in vivo.
• Bacterial challenge efficacy evaluated in rabbits (n=40) with device insertions.
• Stabilization (migration, rotation) assessed in sheep (n=5) with device implants.

Main Results:

• Third-generation envelopes demonstrated equivalent antibiotic elution to second-generation envelopes, remaining above minimal inhibitory concentration (MIC) in vivo for 7 days.
• Both envelope generations significantly reduced bacterial infections compared to no envelope (P <.05).
• Third-generation envelopes showed significantly less device migration (5.5 mm vs 9.9 mm, P <.05) but similar rotation (P = .79) compared to second-generation envelopes.

Conclusions:

• The third-generation TYRX envelope exhibits equivalent preclinical performance to the second-generation envelope.
• It meets all acceptance criteria for antibiotic elution, infection reduction, device stabilization, and absorption.
• This suggests the third-generation envelope is a safe and effective option for preventing infections associated with implantable cardiac devices.